Table 2. Survival and recurrence outcomes in breast cancer survivors who received their initial treatment at our institution (MDA-treated) or elsewhere (OTH-treated).
| Outcome | No. (%) | ||
|---|---|---|---|
| Total cohort, n = 5091 | MDA-treated, n = 4534 | OTH-treated, n = 557 | |
| Overall survival | |||
| Alive | 4583 | 4189 (92.4) | 394 (70.7) |
| Dead | 508 | 345 (7.6) | 163 (29.3) |
| Follow-up period | |||
| Median (range) | 8.7 years (5.0–22.3 years) | 8.6 years (5.0–16.7 years) | 9.0 years (5.0–22.3 years) |
| Interquartile range | 6.6–11.2 years | 6.6–11.1 years | 6.8–12.8 years |
| Time to eventa | |||
| Median (range) | 8.8 years (5.1–19.7 years) | 8.7 years (5.1–17.0 years) | 8.8 years (5.1–19.7 years) |
| Interquartile range | 7.0–11.0 years | 7.0–10.5 years | 7.1–12.0 years |
| Recurrence-free survival | |||
| Local recurrence | 49 (1.0) | 26 (0.6) | 23 (4.1) |
| Local recurrence → death | 4 (0.0) | 1 (0.0) | 3 (0.5) |
| Distant recurrence | 109 (2.1) | 63 (1.4) | 46 (8.3) |
| Distant recurrence → death | 187 (3.7) | 98 (2.2) | 89 (16.0) |
| Local recurrence → distant recurrence | 10 (0.2) | 2 (0.0) | 8 (1.4) |
| Local recurrence → distant recurrence → death | 19 (0.4) | 5 (0.1) | 14 (2.5) |
| Death only | 298 (5.9) | 241 (5.3) | 57 (10.2) |
| Follow-up period | |||
| Median (range) | 8.6 years (5.0–20.1 years) | 8.6 years (5.0–16.7 years) | 8.9 years (5.0–20.1 years) |
| Interquartile range | 6.6–11.1 years | 6.6–11.0 years | 6.8–11.6 |
| Time to event | |||
| Median (range) | 7.5 years (5.0–20.1 years) | 7.7 years (5.1–16.0 years) | 7.2 years (5.0–20.1 years) |
| Interquartile range | 6.0–7.5 years | 6.2–9.7 years | 5.6–9.0 years |
a Median time to event represents the median time to develop the first event among patients who had an event.